The study tackled a stubborn technical problem. Endothelial cells, the thin lining of blood vessels that governs vascular health, are nearly impossible to extract directly from living patients for study. To get around this, the researchers turned to induced pluripotent stem cells, or iPSCs, generated from blood samples of three women with PCOS and three women without the condition. Because iPSC reprogramming resets most environmental epigenetic marks, any defects that persist into cells derived from these lines likely reflect genetic susceptibility or stable epigenetic memory rather than the current hormonal environment of the donor. The team coaxed these stem cells into endothelial cells with high efficiency, producing a controlled platform in which the innate, cell-autonomous properties of PCOS vasculature could be examined in isolation.

The central experiment was elegantly simple. The researchers exposed both PCOS-derived and control endothelial cells to either normal glucose at 5.5 millimolar or high glucose at 30 millimolar, a concentration routinely used to model the hyperglycemic states seen in diabetes, for 24 hours. Under normal glucose, both cell types formed capillary-like tubes on Matrigel with equal competence. Under high glucose, the picture split dramatically. Tube formation, a standard readout of angiogenic capacity, was markedly and significantly impaired in all three PCOS lines, while the control cells carried on as if nothing had happened. The defect was consistent across every independent PCOS cell line tested, a sign that the vulnerability is not an artifact of one donor.

What the researchers found inside the cells explains the functional collapse. Confocal microscopy of the outer mitochondrial membrane protein TOM20 revealed that PCOS endothelial cells exposed to high glucose underwent striking mitochondrial fragmentation, their normally interconnected tubular networks breaking into short, disconnected pieces. Quantitative analysis with the Mitochondrial Network Analysis toolset confirmed reductions in mitochondrial footprint, mean branch length, and the number of branches per network. Control cells maintained their mitochondrial architecture under identical conditions. The dynamics proteins told a subtler story: control cells responded to glucose stress by upregulating the fusion proteins MFN1, MFN2, and OPA1, a known protective maneuver that dilutes damaged mitochondrial DNA, while the PCOS cells failed to mount this compensatory response and instead increased the fission proteins DRP1 and FIS1. In other words, the pathology involves not just susceptibility to injury but an impaired adaptive response to stress.

Functional measurements drove the point home. Using the MitoSOX Red fluorescent probe, the team detected a significant accumulation of mitochondrial reactive oxygen species in high-glucose-treated PCOS endothelial cells but not in controls. Seahorse extracellular flux analysis then showed that the same cells suffered reductions in basal respiration, maximal respiration, ATP production, and spare respiratory capacity, the metabolic reserve that healthy mitochondria keep for emergencies. Control cells showed none of these deficits. Taken together, the data indicate that a single day of hyperglycemia is enough to unmask a latent bioenergetic defect in PCOS endothelium, one that healthy endothelium simply does not share.

The second half of the story concerns myeloperoxidase, or MPO, a heme peroxidase classically produced by neutrophils and monocytes and long recognized as a cardiovascular risk biomarker, particularly in type 2 diabetes, where elevated MPO independently predicts cardiovascular events beyond traditional risk factors. Prior studies had already reported elevated circulating MPO in women with PCOS. What makes the new work provocative is the finding that endothelial cells themselves express MPO. Reverse transcription quantitative PCR detected MPO mRNA in all PCOS and control lines, and western blotting revealed the characteristic autocatalytic MPO fragments at 43 to 47 kilodaltons. After 24 hours of high glucose, MPO mRNA and protein rose significantly in the PCOS cells. Notably, MPO was undetectable in the culture supernatant, indicating that in these endothelial cells the enzyme acts intracellularly rather than being secreted, a localization consistent with recent reports of nuclear MPO in endothelial colony-forming cells from coronary artery disease patients.

The most striking result came from pharmacological intervention. When the researchers pre-treated the cells with 4-aminobenzoic acid hydrazide, or 4-ABAH, a potent MPO inhibitor, the high-glucose-induced surge in mitochondrial ROS was blunted and the impaired tube formation was substantially restored. A mannitol osmotic control confirmed that the damage was driven by glucose itself rather than by osmotic pressure. This suggests that endogenous, intracellular MPO is not merely a passive bystander but an active contributor to the mitochondrial oxidative stress and angiogenic failure that hyperglycemia provokes in PCOS endothelium. The authors are careful to note that pharmacological inhibition alone cannot establish definitive causality without genetic gain- and loss-of-function models, but the convergent evidence is compelling.

To anchor the cellular findings in clinical reality, the team measured serum MPO in 22 treatment-naïve women with PCOS and 20 age- and body mass index-matched controls at National Taiwan University Hospital. The PCOS group averaged 668.6 nanograms per milliliter of MPO compared with 393.9 in controls, a statistically significant difference. The PCOS cohort also showed the expected burden of metabolic comorbidity: 77 percent met criteria for insulin resistance, 50 percent for pre-diabetes, and 50 percent for hypertension, against 10, 0, and 10 percent respectively in controls. Pearson correlation analysis revealed that in the PCOS group, serum MPO rose in parallel with diastolic blood pressure, fasting glucose, and LDL cholesterol, associations absent in controls. Crucially, multivariable regression showed that the MPO-glucose relationship remained significant after adjusting for BMI and insulin, suggesting that hyperglycemia drives MPO elevation independently of insulin resistance, the hallmark traditionally blamed for PCOS metabolic pathology. The association weakened when blood pressure was added to the model, hinting at interconnections among these vascular parameters that future work will need to disentangle.

The study’s implications reach beyond PCOS. It reframes vascular disease risk in these women as stemming partly from a stable, cell-autonomous mitochondrial defect rather than solely from systemic hormonal and metabolic derangements. Because iPSC reprogramming should erase acquired environmental marks, the persistence of the phenotype raises the possibility of genetic susceptibility or durable epigenetic memory, echoing the concept of hormonal imprinting. It also elevates MPO from biomarker to potential therapeutic target, at least in principle, since inhibiting it functionally rescued the cells in vitro. The authors acknowledge limitations: only three iPSC lines per group, a clinical cohort too small for phenotypic subgroup analysis, an acute rather than chronic glucose challenge, and the absence of direct intracellular MPO measurements in patient endothelial cells. Still, the consistency across independent lines, complementary assays, and the parallel clinical cohort gives the model considerable weight.

For the millions of women living with PCOS, the message is a mechanistic warning: the blood vessel lining may already be primed to fail when blood sugar climbs, even before diabetes develops. The half of the PCOS cohort with pre-diabetes in this study illustrates how common that trigger already is. Whether MPO-targeted strategies or aggressive early glucose control can translate this cellular insight into reduced cardiovascular events remains the essential next question, one that the intracellular MPO-mitochondrial axis now provides a concrete framework for testing.

Subject of Research: Mitochondrial dysfunction and myeloperoxidase dysregulation in hyperglycemia-stressed endothelial cells derived from PCOS patient iPSCs

Article Title: Hyperglycemia induces endothelial mitochondrial dysfunction and myeloperoxidase dysregulation in PCOS iPSCs

Article References: Wu, C.-E., Huang, C.-C., Chen, T.-H., Tsou, C.-C., Yang, I.-J., Chang, Y.-Y., Chen, M.-J., & Ho, H.-N. (2026). Hyperglycemia induces endothelial mitochondrial dysfunction and myeloperoxidase dysregulation in PCOS iPSCs. iScience, 29(11), Article 117852. https://doi.org/10.1016/j.isci.2026.117852

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117852

Keywords: PCOS, endothelial dysfunction, mitochondria, myeloperoxidase, hyperglycemia, induced pluripotent stem cells, reactive oxygen species, cardiovascular risk, insulin resistance, angiogenesis, oxidative stress, iScience

The study enrolled 391 adults aged 45 and older in China and compared three groups: 172 long-term Tai Chi practitioners, 72 conventional exercisers who regularly performed square dancing, jogging, or brisk walking, and 147 irregular exercisers. Regular exercise was strictly defined as at least three sessions per week of at least 30 minutes each, sustained for more than one year. By measuring a panel of vascular outcomes and blood biomarkers, the researchers set out to test whether Tai Chi, a mind-body exercise combining slow movement, balance, and breath control, would be associated with healthier arteries than simply being physically inactive or only occasionally active.

To capture vascular health, the team relied on several well-established noninvasive measures. Flow-mediated dilation, or FMD, reflects how well an artery widens in response to increased blood flow, a hallmark of endothelial function. Brachial-ankle pulse wave velocity, or baPWV, gauges arterial stiffness by timing how fast pressure waves travel between the arm and the ankle. The ankle-brachial index, or ABI, screens for peripheral artery disease by comparing blood pressure at the ankle with that in the arm. Carotid intima-media thickness, or IMT, measures the thickness of the inner layers of the carotid artery wall, a structural marker of early atherosclerosis. The researchers also recorded peak systolic velocity, wall shear stress, and resistance index, adding hemodynamic detail to the picture.

After adjusting for covariates and applying a modern statistical approach known as targeted maximum likelihood estimation, along with a Benjamini-Hochberg correction across the seven vascular outcomes, the results showed that Tai Chi practitioners had significantly better vascular measures than irregular exercisers. Compared with the irregular group, Tai Chi practice was associated with higher FMD by 1.39 percentage points, a meaningful gain in endothelial function. It was also linked to lower baPWV by roughly 103 centimeters per second, indicating less arterial stiffness, along with lower ABI, thinner carotid IMT by about 0.09 millimeters, and a lower resistance index, suggesting less resistance to blood flow in the peripheral circulation.

Conventional exercise also outperformed irregular exercise on endothelial function, with a 0.79 percentage point higher FMD than the irregular group. However, when the researchers directly compared Tai Chi practitioners with conventional exercisers, no significant differences emerged after statistical correction. This suggests that the vascular benefits seen in Tai Chi practitioners may not be unique to the slow, meditative art itself, but could reflect the broader effects of sustained, regular physical activity on the cardiovascular system.

Beyond the vascular measures, the team explored whether inflammation and oxidative stress might indirectly link Tai Chi practice to vascular health. They measured blood levels of high-sensitivity C-reactive protein, or hs-CRP, a marker of systemic inflammation, along with tumor necrosis factor-alpha, interleukin-6, interleukin-10, and interleukin-33. On the oxidative stress side, they measured superoxide dismutase, or SOD, an antioxidant enzyme, malondialdehyde, or MDA, a marker of lipid damage from free radicals, and glutathione peroxidase, or GPx, another antioxidant defense molecule. Exploratory analyses pointed to nominal potential indirect associations involving hs-CRP, SOD, and combined inflammatory and oxidative-stress composites, hinting that Tai Chi might partly influence vascular health by dampening chronic inflammation and bolstering antioxidant capacity.

However, the researchers are careful to note that these biomarker findings are exploratory and were not adjusted for multiple comparisons, meaning they should be treated as hypothesis-generating rather than definitive. The cross-sectional design also means the study cannot establish causality; it is possible that people with healthier vasculature are simply more likely to sustain long-term Tai Chi practice, rather than the other way around. The authors emphasize that prospective cohort studies and randomized controlled trials are needed to determine whether Tai Chi truly causes these vascular improvements and whether the biomarker pathways hold up under more rigorous testing.

The study was registered with ClinicalTrials.gov under identifier NCT06307483 and received ethical approval from the Ethics Committee of Beijing Sport University. It was supported by funding from the Tai Chi Laboratory of the Chinese Intangible Cultural Heritage Association Tai Chi Committee, the Special Fund for Basic Scientific Research of Central Universities, the Science and Technology Commission of Shanghai Municipality, and Neil Shen’s SJTU Medical Research Fund. The work reflects a collaboration spanning Beijing Sport University, Shanghai Jiao Tong University, Henan Polytechnic University, and other institutions, with support from the Sports Bureau of Wenxian, Henan Province, and Wenxian People’s Hospital.

For the general public, the takeaway is nuanced. Tai Chi appears to be associated with better vascular function and structure than being irregularly active, and the magnitude of the differences, particularly in arterial stiffness and carotid wall thickness, is notable for a low-impact, accessible exercise. Yet the absence of significant differences from conventional exercise suggests that the key ingredient may be sustained, regular movement itself, whether slow and meditative or brisk and rhythmic. For older adults seeking a gentle, sustainable way to support cardiovascular health, Tai Chi remains a promising option, but the new study stops short of proving it superior to other forms of regular exercise. Larger, longer-term, and randomized studies will be needed to determine whether the ancient practice can truly reshape the arteries, and whether the quiet interplay of inflammation and oxidative stress holds the mechanistic key.

}

Subject of Research: Tai Chi

Article Title: Associations of long-term Tai Chi practice with vascular health in middle-aged and older adults: potential indirect roles of inflammation and oxidative stress – a cross-sectional study

Article References: Associations of long-term Tai Chi practice with vascular health in middle-aged and older adults: potential indirect roles of inflammation and oxidative stress – a cross-sectional study. (n.d.). https://doi.org/10.1186/s12906-026-05645-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05645-3

Keywords: Tai Chi, vascular health, inflammation, oxidative stress, aging, cross-sectional study, flow-mediated dilation, arterial stiffness, Associations, long-term, practice, vascular

The evidence they marshal for the inadequacy of the current model is stark. Therapeutic efforts have long targeted the defining pathological features of dementia: the aggregation of misfolded proteins such as amyloid-β and tau, the loss of synapses, and the death of neurons. Recent drugs that effectively eliminate amyloid plaques from the brain confer only modest benefit, slowing disease progression by roughly 20 to 30 percent in a selected clinical trial population. The authors argue that this discordance between successful removal of the molecular target and minimal-to-modest improvement in functional outcomes raises a fundamental question. If clearing amyloid and tau does not rescue cognition, are these protein deposits truly the primary drivers of dementia, or are they downstream footprints of something deeper?

Their answer lies in metabolism. The human brain is an extraordinarily expensive organ to run. Although it accounts for only a small fraction of body weight, it consumes a disproportionate share of the body’s total energy, and it has essentially no reserve and minimal tolerance for fluctuation. Its function depends on the continuous, precisely regulated delivery and utilization of oxygen and metabolic substrates through a highly efficient and plastic vascular network. Even modest energy dysregulation, well within the range produced by common metabolic disorders, can create a chronic cerebral energy deficit. The immediate consequence is not cell death but the activation of stress-response mechanisms, including the unfolded protein response and the integrated stress response. These responses are initially compensatory, but over time they trigger a gradual erosion of synaptic function and neuronal network integrity.

The epidemiological evidence supporting a systemic view is substantial. Declining metabolic and vascular health across the life course closely parallels cognitive decline. Conditions that impair systemic energy homeostasis, particularly during midlife, including diabetes, hypertension, and dyslipidemia, are consistently associated with an increased risk of dementia, and they are also linked to both Alzheimer’s disease pathology and cerebrovascular damage. Conversely, factors associated with efficient energy production and delivery, such as physical activity and cardiovascular fitness, are among the most robust protective factors against brain aging and neurodegeneration. A healthy brain, the authors contend, requires the integrity of the physiological systems that regulate energy production and distribution throughout the body, not merely the absence of pathology within the brain itself.

Mechanistically, multiple aging processes converge on this energetic axis. Brain insulin resistance reduces the efficiency with which cells utilize available energy. Vascular dysfunction limits the delivery of oxygen and metabolic substrates to tissue. Chronic inflammation disrupts homeostatic signaling while simultaneously increasing metabolic demand. Together, these alterations create a state of energetic insufficiency that compromises neuronal function, impairs resilience to stress, and ultimately contributes to the development of dementia. The vascular system occupies a central position at this intersection, sitting precisely where systemic energy dysregulation meets neurodegeneration.

One of the most intriguing threads in the argument involves subtle signs of aging that seem, on the surface, unrelated to cognition. Deficits in sensorimotor function, such as slow gait, oculomotor impairment, and diminished olfaction, are early indicators of future cognitive decline. The authors suggest that these seemingly distinct aging phenotypes may share common systemic drivers, including inflammation, impaired lipid metabolism, vascular pathology, and compromised mitochondrial health. All are components of the system responsible for maintaining energy homeostasis, and that system progressively loses efficiency with age and disease, narrowing the margin within which organs can function. The brain, operating closest to that margin, is the first place the narrowing becomes clinically visible.

Chronic energy insufficiency also has downstream consequences for tissue maintenance and repair that may feed back into the problem. A sustained deficit in cellular energy availability promotes cellular senescence, impaired proteostasis, and remodeling of the extracellular matrix. Senescent cells alter the composition and physical properties of the extracellular environment, favoring fibrosis, collagen deposition, and cross-linking. These changes increase tissue stiffness, disrupt microvascular function, and impair perfusion and oxygen delivery, which in turn damages mitochondrial health and further erodes energy sufficiency. The authors describe this as a senescence-stiffening loop, a self-reinforcing cycle in which energy failure drives structural change and structural change deepens energy failure. Even the aging brain, generally considered less fibrotic than other organs, shows measurable changes in extracellular matrix composition, basement membrane thickening, and vascular stiffening, all of which contribute to impaired neurovascular coupling and reduced adaptability of cerebral blood flow.

This framework offers a potential resolution to one of the most stubborn paradoxes in Alzheimer’s research: why some resilient individuals with substantial neuropathology remain cognitively intact while others with far less pathology develop severe impairment. The authors propose that the difference may lie in the organism’s capacity to maintain energy homeostasis. Recent work supports this idea, showing that preserved mitochondrial bioenergetics distinguishes asymptomatic individuals from symptomatic ones in the presence of Alzheimer’s disease pathology. In other words, amyloid and tau may set the stage, but the body’s energetic resilience determines whether the play is performed. The defining features of dementia, from protein aggregation to synaptic loss to neuronal death, may represent downstream manifestations of prolonged energetic insufficiency in the most energy-dependent organ in the body.

The clinical implications, if the hypothesis is correct, are profound. Treating dementia by targeting isolated molecular features within the brain may be fundamentally misdirected, because a failing energy-regulation system cannot be rescued by correcting a single downstream lesion. Prevention and treatment must instead focus on preserving energetic resilience across the entire life course, maintaining the capacity to efficiently produce, distribute, and utilize energy. The consistent link between midlife metabolic and vascular health and preserved brain function into late life suggests that the brain may track the body’s ability to meet its energy demands decades before any cognitive symptom appears. That would reframe midlife blood pressure, glucose, and lipid control not merely as heart disease prevention but as dementia prevention.

The authors are careful to note what their argument does not claim. It does not imply that brain-specific processes are irrelevant, nor that all dementias are the same. Genetic forms of dementia and distinct neurodegenerative mechanisms clearly exist, and etiologically distinct forms may represent special cases within a broader framework in which systemic energetic failure is the dominant driver of late-life cognitive impairment. But the broader message is hard to dismiss: the brain, by operating at the very limits of energetic stability, is simply where the body’s slow systemic failure becomes impossible to ignore. If the hypothesis withstands experimental scrutiny, the search for dementia’s cure may move out of the brain and into the bloodstream, the vasculature, and the mitochondria that power every cell in the body.

Subject of Research: Systemic energy dysregulation as a proposed primary mechanism of dementia

Article Title: Is dementia really a brain disease?

Article References: Tian, Q., Walker, K. A., & Ferrucci, L. (2026). Is dementia really a brain disease?. PLOS Aging and Health, 1(3), e0000035. https://doi.org/10.1371/journal.page.0000035

Image Credits: AI Generated

DOI: 10.1371/journal.page.0000035

Keywords: dementia, Alzheimer's disease, energy metabolism, mitochondria, vascular health, brain aging, insulin resistance, inflammation, amyloid-beta, tau, cellular senescence, neurodegeneration

The endothelium, the delicate single layer of cells lining the interior of every blood vessel, is far more than passive plumbing. It actively regulates vascular tone by releasing vasodilating and vasoconstricting compounds, controls oxidative processes, modulates cell adhesion, and influences arterial stiffness. When the endothelium falters, vessels stiffen, their dilatory responses weaken, and the earliest silent stages of cardiovascular disease take hold. Flow-mediated dilation of the brachial artery, measured with high-resolution ultrasound after a temporary ischemic stimulus, captures this dysfunction early and tracks closely with coronary artery function, which is why the research team led by Simon Iskra and Armin Paravlić of the University of Ljubljana centered their analysis on it.

To assemble the evidence, the researchers searched six major databases from inception through multiple updated searches in 2023, 2025 and 2026, screening nearly 1,900 records against strict PICOS criteria. Only randomized controlled trials in adults that reported brachial artery flow-mediated dilation alongside at least one secondary outcome made the cut. The final pool spanned healthy volunteers and patients with cardiovascular disease, metabolic syndrome, diabetes, kidney disease, cancer, and even mental and neurological disorders. Participants ranged from about 20 to 78 years old, 43 percent were women, and interventions lasted from four to 26 weeks, with roughly two-thirds of study arms using continuous training and one-third using interval formats.

The headline result survived every robustness check the team threw at it. A random-effects model yielded a mean difference of 2.35 percent in flow-mediated dilation, a fixed-effects model produced 1.90 percent, and a trim-and-fill adjustment for publication bias still left a significant adjusted estimate of 1.74 percent. Sensitivity analysis removing the single largest study did not change the conclusion. Heterogeneity was high, as expected when pooling trials across such diverse populations and protocols, but the direction and clinical relevance of the effect were consistent. By the classification scheme the authors applied, the pooled gain qualifies as small but clinically meaningful, sitting above the 1 percent threshold considered the minimal clinically important difference.

The most novel contribution, however, lies in the meta-regression, which asked which physiological changes actually drive the vascular improvements. Four clusters emerged as significant moderators. Greater reductions in body weight and body fat were associated with larger gains in endothelial function, with regression coefficients of -4.021 and -1.721 respectively. Drops in systolic and diastolic blood pressure also tracked with better flow-mediated dilation, at coefficients of -0.525 and -0.484. On the positive side, improvements in maximal oxygen uptake, the classic index of cardiorespiratory fitness, showed a strong association with endothelial gains at a coefficient of 0.656, and changes in insulin levels moderated the effect as well. Notably, blood lipids, fasting glucose, HbA1c, and insulin resistance measured by HOMA-IR did not significantly moderate the vascular response, suggesting lipid and glucose improvements run on partly independent tracks.

Beneath these statistical associations lies a coherent mechanistic story. During aerobic exercise, blood flow to working muscles surges, subjecting the vessel walls to elevated shear stress. This mechanical signal activates endothelial nitric oxide synthase, boosting production of nitric oxide, the principal vasodilator of healthy arteries. The meta-analysis confirmed this biochemistry in blood: nitric oxide and its metabolites rose substantially, with standardized mean differences of 1.23 for both, while endothelin-1, the vessels’ chief constricting agent, fell moderately. Enhanced nitric oxide bioavailability combined with reduced endothelin-1 shifts vascular tone toward dilation, plausibly explaining much of the measured improvement in flow-mediated dilation, even though the biomarkers themselves did not reach statistical significance as moderators, likely because relatively few studies measured them.

The hemodynamic findings add another layer. Aerobic training produced small but significant reductions in systolic pressure, diastolic pressure, and mean arterial pressure, and the meta-regression tied these blood pressure drops directly to endothelial gains. The authors interpret this as evidence of a feedback loop: healthier endothelia dilate more readily, lowering vascular resistance and pressure, which in turn protects the vessel wall. Arterial stiffness told a subtler tale. Peripheral stiffness, measured at the brachial-ankle segment, decreased significantly, but central stiffness, measured at the carotid-femoral segment, and the augmentation index did not change. The researchers attribute this to the time course of vascular remodeling, since peripheral arteries adapt faster than the stiffer central vessels, and to the small number of trials that measured central outcomes alongside flow-mediated dilation.

Cardiorespiratory fitness emerged as perhaps the most intriguing partner in the adaptation. Maximal oxygen uptake rose moderately across trials, and the stronger the fitness gains, the stronger the endothelial improvements. The relationship is likely bidirectional. Repeated shear stress from training enhances nitric oxide signaling and vascular homeostasis, while preserved endothelial function optimizes skeletal muscle perfusion and oxygen delivery, supporting further fitness gains. The authors caution that because the meta-regression works at the study level, causality cannot be established; the pattern reflects interconnected adaptations rather than a simple cause-and-effect chain. Still, the convergence of fitness, body composition, blood pressure, and insulin changes as moderators paints exercise as a multi-front intervention rather than a single-target drug.

Body composition results carried their own surprise. Even though the analysis excluded trials that combined exercise with dieting, aerobic training alone significantly reduced body weight, body mass index, and body fat percentage, with no change in skeletal muscle mass. The regression confirmed that fat loss amplified the vascular benefit, and the authors suggest that shrinking adipose tissue dampens chronic low-grade inflammation, a process tightly linked to endothelial health. Inflammation markers moved in the expected direction, with a small significant fall in C-reactive protein and a moderate, near-significant decrease in TNF-alpha. Lipid changes were real but modest, with small rises in HDL cholesterol and small falls in LDL and triglycerides, while glucose metabolism improved through fasting glucose, HbA1c, and insulin resistance, even without significant changes in insulin itself.

The authors are candid about limitations. The restriction to trials reporting brachial artery flow-mediated dilation means conclusions may not generalize to other endothelial assessments. Flow-mediated dilation tends to normalize over longer interventions as structural remodeling proceeds, so pooled changes may understate peak functional adaptation. Pooling healthy and clinical populations yields general tendencies rather than disease-specific prescriptions, and the use of standardized mean differences for secondary outcomes, while necessary given heterogeneous measurement methods, obscures absolute changes. Publication bias was detected for the primary outcome and several secondary markers, though corrections preserved the core finding. Even so, the message is hard to dismiss: aerobic exercise acts simultaneously on fat mass, fitness, blood pressure, insulin regulation, nitric oxide signaling, and inflammation, and these converging pathways collectively rebuild endothelial function. For clinicians and the public alike, the analysis reinforces aerobic training as one of the most powerful non-pharmacological tools available for protecting the vascular system, with benefits that compound across nearly every measurable dimension of cardiovascular health.

Subject of Research: Effects of aerobic exercise on endothelial function and cardiovascular disease markers

Article Title: Impact of Aerobic Exercise on Endothelial Function and Other Cardiovascular Disease Markers in Health and Disease: A Systematic Review and Meta-analysis with Meta-regression of Randomized Controlled Trials

Article References: Iskra, S., Turnšek, G., Drole, K., & Paravlić, A. (2026). Impact of Aerobic Exercise on Endothelial Function and Other Cardiovascular Disease Markers in Health and Disease: A Systematic Review and Meta-analysis with Meta-regression of Randomized Controlled Trials. Sports Medicine – Open, 12(1), Article 150. https://doi.org/10.1186/s40798-026-01110-0

Image Credits: AI Generated

DOI: 10.1186/s40798-026-01110-0

Keywords: aerobic exercise, endothelial function, flow-mediated dilation, cardiovascular disease, meta-analysis, nitric oxide, blood pressure, cardiorespiratory fitness, body composition, insulin, arterial stiffness, vascular health

To understand why the framework matters, it helps to start with the physics. Endothelial cells are not passive pipes; they are mechanosensors constantly bathed in shear stress, the frictional force exerted by flowing blood. Where flow is smooth and laminar, endothelial cells align with the flow direction, produce nitric oxide, suppress inflammation and maintain a quiescent, anti-atherogenic state. Where flow is low or oscillatory, typically at arterial branch points and curvatures, the cells experience turbulent, reversing forces that activate inflammatory transcription factors, reprogram metabolism and, critically, induce DNA damage responses. Studies cited in the review show that disturbed flow promotes endothelial senescence through p53-dependent pathways, and that oscillatory shear can activate the STING innate immune pathway, accelerating both senescence and atherosclerosis in experimental models.

The metabolic half of the equation is equally detailed. Hyperglycaemia, dyslipidaemia, uraemic toxins from failing kidneys, hepatic stress from fatty liver disease, inflammatory cytokines such as tumour necrosis factor alpha and oxidative injury all converge on a remarkably consistent set of intracellular targets. These include the p53/p21 and p16/pRB tumour-suppressor axes that enforce cell-cycle arrest, the decline of NAD+ and sirtuin activity that normally protects genomic integrity, mitochondrial dysfunction that floods the cell with reactive oxygen species, and a metabolic rewiring toward glycolysis and altered fatty acid handling. Senescent endothelial cells, the review notes, can even sustain their own inflammatory secretory phenotype, the so-called SASP, through enhanced fatty acid oxidation, creating a self-perpetuating loop of vascular inflammation.

What distinguishes this review from earlier accounts of endothelial ageing is its insistence on the mechanometabolic intersection. Matrix stiffness, which increases as arteries age and stiffen, feeds back on endothelial cells through mechanosensitive channels such as Piezo1, altering their response to shear. Disturbed flow induces metabolic reprogramming via HIF-1alpha and AMPK-driven glycolysis, and single-cell RNA sequencing studies reveal that cells exposed to disturbed flow adopt distinct transcriptomic and chromatin accessibility signatures. Epigenetic mechanisms add another layer: flow-dependent DNA methylation, DNMT1 recruitment, mechanosensitive super-enhancers and even histone lactylation driven by metabolic byproducts all shape which genes an endothelial cell can express. Metabolism, in other words, is not merely fuel; it is a regulator of chromatin, and mechanical forces regulate metabolism.

The authors are explicit that this framework is operational rather than universally standardised. They use cardiometabolic vascular disease, or CMVD, as an umbrella term for vascular injury arising from interacting metabolic, renal and cardiovascular stress, echoing the cardiovascular-kidney-metabolic health concept promoted by the American Heart Association. But they resist the temptation to declare endothelial senescence a universal primary cause of vascular disease. Instead, they describe it as a context-dependent amplifier, a mechanism that magnifies injury where mechanical vulnerability and metabolic load coincide, and a testable translational model whose validity must be demonstrated compartment by compartment.

That translational ambition is where the review becomes most clinically interesting. The authors catalogue the functional anchors clinicians already use: flow-mediated dilatation of the brachial artery for macrovascular endothelial function, carotid-femoral pulse-wave velocity for aortic stiffness, coronary flow reserve and the index of microcirculatory resistance for the coronary microvasculature. Each provides a compartment-specific readout, yet none is a direct senescence assay. To bridge that gap, the review proposes a staged validation strategy that combines confirmation of endothelial identity, convergent senescence markers such as p16, senescence-associated beta-galactosidase and SASP components, measures from circulating endothelial cells or extracellular vesicles, vascular function testing and, ultimately, organ-specific clinical outcomes. Circulating endothelial cells isolated from blood samples, one cited study suggests, could offer a practical window on endothelial senescence without requiring arterial biopsy.

The framework is then stress-tested against three organ contexts. In heart failure with preserved ejection fraction, a condition disproportionately affecting older women, coronary microvascular endothelial inflammation and senescence have been implicated in animal models, and SIRT6 deficiency worsens the diabetic form of the disease in mice, but human evidence remains heterogeneous. In chronic kidney disease, glomerular endothelial senescence drives age-related kidney pathology through plasminogen activator inhibitor-1, and pro-senescent niches organised by matrix proteins such as fibrillin-1 have been described around peritubular capillaries. In metabolic dysfunction-associated steatotic liver disease, aged liver sinusoidal endothelial cells lose their fenestrations and defensive capacity, aggravating hepatic metabolic dysfunction. Across all three, the strongest evidence remains preclinical or mixed translational, a limitation the authors state plainly rather than obscure.

One of the most consequential threads concerns biological sex. Endothelial function declines measurably across the menopause transition, linked to falling estradiol and rising oxidative stress, and nitric oxide itself appears to inhibit endothelial senescence, suggesting a protective mechanism lost after menopause. Yet direct evidence from human arteries complicates the simple story: a study of patients with atherosclerosis found that senescence and inflamm-ageing were associated with endothelial dysfunction in men but not women. The review concludes that sex-disaggregated mechanistic data remain sparse, and that any translational framework claiming general validity must eventually explain why the same senescence machinery may behave differently in female and male vessels.

The therapeutic implications are tantalising but tempered. Senolytic drugs, which clear senescent cells, have ameliorated large-artery stiffening and endothelial dysfunction in aged animals, and habitual exercise in humans is associated with reduced endothelial senescence and better vascular function, partly through enhanced mitophagy in coronary endothelium. NAD+-boosting strategies, sirtuin activation and anti-inflammatory interventions all have preclinical support. But the review’s staged validation strategy is a warning against premature translation: without validated senescence biomarkers in accessible compartments, trials cannot reliably identify which patients carry a mechanometabolic senescence burden or measure whether it has been relieved.

What the review ultimately offers is a map rather than a verdict. It gathers human tissue data, clinical physiology, animal genetics, flow-controlled experiments and single-cell omics into a single causal architecture in which haemodynamic vulnerability and cardiometabolic load jointly push endothelial cells toward senescence, and senescent endothelium in turn stiffens arteries, narrows microvessels and feeds inflammation back into the systemic circulation. The authors’ insistence that the framework is an amplifier, not a universal primary cause, is precisely what makes it scientifically useful: it generates falsifiable predictions about where in the vasculature senescence should accumulate, which biomarkers should track it, and which interventions should relieve it. If those predictions hold in the staged validation the authors propose, the convergence of fluid mechanics and metabolism at the endothelial surface could become one of the organising principles of vascular medicine for the age of cardiometabolic disease.

Subject of Research: Mechanometabolic endothelial senescence linking haemodynamic stress and metabolic load to cardiometabolic vascular disease and vascular ageing

Article Title: Mechanometabolic endothelial senescence as a translational framework for cardiometabolic vascular disease and vascular ageing

Article References: Lanlan, L., Fan, G., Ran, Z., Xiaoqing, Z., Yitong, C., Jingjing, Z., Lei, L., & Jianhua, F. (2026). Mechanometabolic endothelial senescence as a translational framework for cardiometabolic vascular disease and vascular ageing. Molecular Biology Reports, 53(1), Article 1683. https://doi.org/10.1007/s11033-026-12792-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12792-w

Keywords: endothelial senescence, mechanotransduction, disturbed flow, vascular ageing, cardiometabolic disease, SASP, sirtuins, arterial stiffness, HFpEF, chronic kidney disease, MASLD, sex differences

The research team recruited 21 adults aged 35 to 68, dividing them into 11 controls and 10 individuals with long COVID. Every participant had a documented history of SARS-CoV-2 infection, but the two groups differed sharply in the severity of the acute illness and in their recovery. The controls had all experienced asymptomatic or mild infections and reported no lingering symptoms. The long COVID group, by contrast, had suffered moderate-to-critical disease: 60 percent required hospitalization, 60 percent needed oxygen therapy, and one person required mechanical ventilation. At the time of testing, roughly three years after infection, they continued to report fatigue, exercise intolerance, breathlessness, and headaches, and their scores on the Post-COVID-19 Functional Status Scale indicated substantially greater functional limitation than the controls.

To disentangle the possible mechanisms behind this persistent limitation, the investigators designed a three-visit protocol that separated each measurement from the others. On the first visit, participants completed a symptom-limited cardiopulmonary exercise test on a cycle ergometer, with breath-by-breath gas exchange analysis, continuous electrocardiography, and blood pressure monitoring. The second visit was devoted to transthoracic echocardiography, including advanced speckle-tracking analyses of myocardial work. The third visit assessed endothelial function using brachial artery flow-mediated dilation, a noninvasive ultrasound technique in which a blood pressure cuff is inflated for five minutes to induce ischemia and the subsequent surge of blood upon release is used to probe how well the artery dilates. Participants abstained from caffeine, alcohol, and strenuous activity before each session to prevent interference between measurements.

The exercise testing revealed clear and quantifiable deficits. Compared with controls, the long COVID group achieved a lower peak oxygen uptake, a lower predicted peak oxygen uptake relative to reference values, and a lower oxygen uptake at the first ventilatory threshold, the point during incremental exercise where metabolism begins to shift toward anaerobic contribution. These differences carried large effect sizes, indicating that the impairment was not marginal. Because both maximal and submaximal aerobic capacity were reduced, the results suggest that everyday activities, not just athletic performance, demand more physiological effort from these individuals than from their fully recovered counterparts.

The vascular findings were even more striking. Flow-mediated dilation was dramatically lower in the long COVID group, with a Cohen’s d of 2.30, an effect size that is exceptionally large for a between-group comparison in human vascular physiology. Crucially, the team also measured the shear-rate stimulus, the frictional force that flowing blood exerts on the vessel wall and that normally triggers the endothelium to release nitric oxide and other vasodilators. Peak shear rate, the area under the shear-rate curve during the hyperemic period, and the area under the curve up to maximal vasodilation were all significantly reduced in the long COVID participants. This means the problem involves not only a blunted vasodilatory response but also a diminished hyperemic signal, a double hit to the mechanisms that normally match blood flow to metabolic demand.

The researchers took care to ensure that the difference in flow-mediated dilation was not an artifact of differing artery sizes. Allometric scaling of log-transformed baseline and peak diameters showed no significant group-by-diameter interaction, and the between-group difference remained significant after adjustment for baseline diameter. The difference also persisted after statistical adjustment for age, sex, body composition, and comorbidities, strengthening the conclusion that the vascular impairment is a genuine feature of the long COVID phenotype rather than a byproduct of the higher body mass index and obesity prevalence observed in this group.

Perhaps the most informative result came from the correlation analyses. Within the long COVID group, flow-mediated dilation was positively and significantly associated with both peak oxygen uptake and predicted peak oxygen uptake, meaning that individuals with better endothelial function tended to have better aerobic capacity. No such association appeared among the controls, whose vascular function was uniformly good. This pattern supports the idea that, in long COVID, the state of the peripheral vasculature becomes a rate-limiting factor for exercise performance, constraining oxygen delivery to skeletal muscle in a way that does not occur in healthy vasculature with reserve capacity to spare.

The heart, meanwhile, told a different story. Conventional echocardiographic measures, including left ventricular ejection fraction, volumes, and global longitudinal strain, were indistinguishable between groups, as were the myocardial work indices derived from pressure-strain analysis: global work index, global constructive work, global wasted work, and global work efficiency. Myocardial work integrates ventricular deformation with afterload and can detect subtle dysfunction that conventional parameters miss, yet even this sensitive approach found no group differences. Exploratory analyses did reveal intriguing internal patterns: in the long COVID group, lower global work index was associated with greater ventilatory drive and poorer ventilatory efficiency during exercise, and with higher body mass index, hinting at interactions between metabolic status, breathing mechanics, and cardiac mechanics that deserve further study in larger cohorts.

Taken together, the data sketch a coherent physiological account of long COVID exercise intolerance. Persistent endothelial injury after SARS-CoV-2 infection, plausibly driven by chronic inflammation, oxidative stress, and reduced nitric oxide bioavailability, compromises the ability of conduit and resistance vessels to dilate appropriately during exercise. The result is a peripheral limit on oxygen delivery that manifests as reduced aerobic capacity, while the central pump continues to function within normal limits. This peripheral mechanism aligns with earlier studies conducted one and two years after infection, but the present work extends the timeline considerably, showing that these abnormalities persist well into the third year after the acute illness.

The authors are careful to note the limitations of their study. It was observational, cross-sectional, and single-center, with a modest sample size, so the findings are hypothesis-generating rather than definitive. The long COVID cohort consisted predominantly of people with previous moderate-to-critical illness, and the controls all had prior asymptomatic or mild infection, so the results may not generalize to the full spectrum of post-COVID conditions. The cohort was also predominantly composed of individuals with overweight or obesity, and the study was not powered to detect sex or race differences. Even so, the large effect sizes and the a priori power calculation lend credibility to the central conclusion. Clinically, the work argues for evaluating vascular health, not just cardiac function, in patients with persistent post-COVID exercise intolerance, and for cardiometabolic risk management alongside structured rehabilitation. Whether improving endothelial function can restore exercise tolerance remains a critical question for future interventional trials.

Subject of Research: Persistent endothelial dysfunction and exercise intolerance in long COVID three years after SARS-CoV-2 infection

Article Title: Persistent endothelial dysfunction is associated with exercise intolerance in adults despite preserved myocardial work 3 years after SARS‐CoV‐2 infection

Article References: de Araújo Alves, C. C., Goulart, C. D. L., D'Ávila, L., de Souza Silva, B. H. E., Alves, I. M., Aguiar, B. V. S., Conde, C., Stein, R., & Cipriano, G., Jr. (2026). Persistent endothelial dysfunction is associated with exercise intolerance in adults despite preserved myocardial work 3 years after SARS‐CoV‐2 infection. Physiological Reports, 14(19), Article e71103. https://doi.org/10.14814/phy2.71103

Image Credits: AI Generated

DOI: 10.14814/phy2.71103

Keywords: long COVID, endothelial dysfunction, flow-mediated dilation, exercise intolerance, myocardial work, cardiopulmonary exercise testing, SARS-CoV-2, vascular function, peak oxygen uptake, echocardiography, nitric oxide, post-COVID condition